Achieved Sequential Revenue Growth of 28% in Third
Quarter of 2020, Driven by Detection Product and Therapy Product Revenue Growth
of 44% and 251%, Respectively

Net Loss Improved by $1.2 million to $1.8 million in
the Third Quarter of 2020 as Compared to $3.0 million in the Third Quarter of

New AI Offering Expands Focus from Current Age Based
Detection to 2 Year Risk Assessment and Personalized Screening Regimen

New Partnership Agreement Enhances Commercial Access
to Enterprise and Integrated Delivery Systems

Conference Call Today at 4:30 p.m. ET

N.H. – November 5, 2020 –  iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader
providing innovative cancer detection and therapy solutions, today
reported its financial and operating results for the three and nine months
ended September 30, 2020.


  • ProFound AI Risk, the first and only commercially
    available clinical decision support tool providing accurate two-year breast
    cancer risk estimation personalized for each woman, currently available on an introductory basis for 2D
    mammography in the U.S. and Europe
    ● Data published recently
    in the peer-reviewed journal, Radiology,
    showed that our technology significantly outperformed existing breast cancer
    risk models
  • Signed
    distribution agreement with Change Healthcare, a leading independent healthcare technology company focused
    on insights, innovation and accelerating the transformation of the U.S.
    healthcare system, that will expand access to ProFound AI™ for more hospitals
    and imaging centers across North America
  • Presented
    updated positive clinical data for Xoft® Brain IORT demonstrating significant improvement in overall survival
    and local progression-free survival in patients with recurrent GBM treated with
    Xoft versus patients treated with external beam radiation therapy and systemic
  • Cash balance of $22.6 million at the end of the third
    quarter of 2020

View Webcast

Full Results